Efficacy of Ayurveda intervention in themanagement of menorrhagia (Raktapradara) â?? A Randomized control trial

CENTRAL COUNCIL FOR RESEARCH IN AYURVEDIC SCIENCES0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年5月29日

试验速览

暂无简介。

•1.Women age between 20-50 years.
•2.Patient having regular (21-35 days) cycle with Heavy Menstrual Blood (HMB) loss, subjectively or objectively deï¬?ned (Pictorial Blood Assessment Chart â??PBAC3 score more than 100 points) or prolonged bleeding (bleeding more than >7days) for THREE consecutive cycles.
•3.Patient willing to participate in study

•1.Hb % < 7gm%.
•2.Lactating mother
•3.Bleeding from the polyps, uterine fibroid, erosion and cancer.
•4.Pregnancy and its Complication.
•5.History of the bleeding from the site other than the uterus.
•6.Women on Anti -Coagulant therapy.
•7.Patient with raised liver enzymes twice the upper limit of normal & creatinine more than 1.4 mg%, poorly controlled Hypertension ( >160/100 mm of Hg), poorly controlled Diabetes Mellitus{B.S. (F) > 130 mg% and / or Blood Sugar (2 hr. PP) >250 mg% & HbA1c > 6.5%}.
•8.Patients on Combined contraceptive pills/IUCD/DMPA
•9.Patients on prolonged ( > 6 weeks) medication with corticosteroids, antidepressants, anti-cholinergics, anticoagulant etc. or any other drugs that may have an influence on the outcome of the study.
•10.History of uncontrolled hyperthyroidism or hypothyroidism.
•11.Patients who have a past history of Atrial Fibrillation, Acute Coronary Syndrome, Myocardial Infarction, Stroke or Severe Arrhythmia in the last 6 months.
•12.History of tuberculosis, Pelvic Inflammatory Diseases (PID).
•13.Patients with any other major systemic illness.
•14.Patients who are currently participating in any other clinical trial
•15.H/o hypersensitivity to the trial drug or any of its ingredients Any other condition which the Principal Investigator thinks may jeopardize the study.
•16.Any other condition which the Principal Investigator thinks may jeopardize the study.

发起方